Search

for
Search:

Sort by

Research

17 / 17 results

research Real-Life Effectiveness and Safety of Baricitinib in 17 Japanese Patients With Alopecia Areata: A 60-Week Single Center Study

January 2025 in “Journal of Cutaneous Immunology and Allergy”

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

research Baricitinib for the Treatment of Alopecia Areata

6 citations, May 2023 in “Drugs”

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

research Baricitinib Achieved Complete or Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials

January 2025 in “SKIN The Journal of Cutaneous Medicine”

Baricitinib significantly regrows hair in severe alopecia areata patients.

Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials

research Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials

3 citations, June 2023 in “Journal of dermatological treatment”

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

research Evidence-Based Data on Duration of Baricitinib Treatment for Severe Alopecia Areata

January 2025 in “SKIN The Journal of Cutaneous Medicine”

Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.

The Relative Efficacy of Monotherapy With Janus Kinase Inhibitors, Dupilumab and Apremilast in Adults With Alopecia Areata: Network Meta-Analyses of Clinical Trials

research The Relative Efficacy of Monotherapy With Janus Kinase Inhibitors, Dupilumab and Apremilast in Adults With Alopecia Areata: Network Meta-Analyses of Clinical Trials

2 citations, July 2023 in “Journal of cosmetic dermatology”

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

research Clinical Experiences on Alopecia Areata Treatment with Tofacitinib: A Study of 63 Patients

17 citations, January 2019 in “Dermatologic Therapy”

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata

research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata

42 citations, November 2018 in “Archives of dermatological research”

Apremilast was not effective in treating moderate-to-severe alopecia areata.

research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

1 citations, September 2023 in “Dermatology and Therapy”

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

September 2023 in “British Journal of Dermatology”

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

20 citations, March 2023 in “American Journal of Clinical Dermatology”

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

research The Use of Phosphodiesterase Inhibitors for the Treatment of Alopecia

3 citations, April 2019 in “Journal of Dermatological Treatment”

Caffeine shows promise for treating some types of hair loss, but more research is needed.

research Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata

55 citations, October 2019 in “Dermatology and therapy”

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.